Artiva Biotherapeutics, Inc. announced that it expects to receive $80.552315 million in funding from 5AM Venture Management, LLC, venBio LLC, RA Capital Management, L.P., Medivate Partners LLC, Green Cross Holdings Corporation, Green Cross Lab Cell Corporation
On the same day, the company issued 15,600,000 shares for proceeds of $78,000,000 in its first tranche closing. The transaction included participation from new lead investors, 5AM Ventures VI, L.P., a fund managed by 5AM Venture Management LLC for 3,700,000 shares, venBio Global Strategic Fund III, L.P., a fund managed by venBio LLC for 3,700,000 shares, and RA Capital Healthcare Fund, L.P. for 2,475,340 shares, Blackwell Partners LLC-Series A for 299,660 shares, and RA Capital Nexus Fund, L.P. for 925,000 shares, funds managed by RA Capital Management, L.P. The transaction also included participation from new investor, Medivate-DA value fund No.03, managed by Medivate Partners LLC for 800,000 shares, existing investors, Green Cross Holdings Corporation (KOSE:A005250) for 1,660,000 shares, and Green Cross Lab Cell Corporation (KOSDAQ:A144510) for 440,000 shares. As a part of the transaction, Brian Daniels of 5AM Venture Management LLC, Laura Stoppel of RA Capital Management, L.P., and Yvonne Yamanaka of venBio LLC will join the company's board.